Company

YIRUI Pharmaceutical Technology

YIRUI Pharmaceutical Technology develops targeted small molecule drugs for autoimmune and inflammatory diseases.

About

Founded in 2018 and based in Hangzhou, China, YIRUI Pharmaceutical Technology researches and develops small molecule targeted drugs for autoimmune diseases, diabetic complications, and chronic inflammation. Its lead candidate, YR-001, is in Phase II clinical trials in the United States for autoimmune skin diseases. In December 2023, the company raised an undisclosed amount led by Tailong VC, with participation from Tianlong Group and Hangzhou Win-Light Investment Co., Ltd. The funding supports clinical trials and other projects.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in